文献速递乳腺癌消化系统肿瘤

Margetuximab(MGAH22)一种Fc修饰嵌合单克隆抗体在HER2阳性晚期实体瘤患者中的首次人体1期研究

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.
PubMed 文献 · Ann Oncol · 2017-01-01

本研究为margetuximab在HER2过表达晚期实体瘤患者中的首次人体1期研究,66例患者分别接受每4周用药3次(0.1-6.0 mg/kg)或每3周1次(10-18 mg/kg)静脉输注。两种方案均未达到最大耐受剂量,治疗耐受良好,60例可评估患者中确认部分缓解7例(12%)、疾病稳定30例(50%),乳腺癌可评估患者中18/23例(78%)出现肿瘤缩小。

要点

  • Margetuximab在HER2阳性晚期实体瘤中耐受良好,两种给药方案均未达到最大耐受剂量。
  • 60例可评估患者中确认部分缓解7例(12%),疾病稳定30例(50%)。
  • 乳腺癌可评估患者中18/23例(78%)出现肿瘤缩小,包括缓解持续超过30周者。

核心结论

  • Margetuximab耐受良好,单药具有有前景的抗肿瘤活性,作为单药及联合其他治疗药物的进一步开发正在进行中。

研究设计与样本

  • 首次人体1期研究,纳入HER2阳性乳腺癌或胃癌或其他HER2过表达癌且无标准治疗可用的患者。
  • 患者接受margetuximab静脉输注,方案A为0.1-6.0 mg/kg每4周用药3次,方案B为10-18 mg/kg每3周1次。
  • 共66例患者接受margetuximab,其中方案A 34例,方案B 32例。

主要发现

  • 两种方案均未达到最大耐受剂量。
  • 治疗耐受良好,毒性主要为1级和2级,包括发热、恶心、贫血、腹泻和乏力等全身症状。
  • 60例可评估患者中,确认部分缓解7例(12%),疾病稳定30例(50%)。
  • 这些患者中26例(70%)既往接受过HER2靶向治疗。
  • 乳腺癌可评估患者中超过半数(18/23,78%)出现肿瘤缩小,包括缓解持续超过30周者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Margetuximab is an anti-HER2 antibody that binds with elevated affinity to both the lower and higher affinity forms of CD16A, an Fc-receptor important for antibody dependent cell-mediated cytotoxicity (ADCC) against tumor cells. A Phase 1 study was initiated to evaluate the toxicity profile, maximum tolerated dose (MTD), pharmacokinetics, and antitumor activity of margetuximab in patients with HER2-overexpressing carcinomas. PATIENTS AND METHODS: Patients with HER2-positive breast or gastric cancer, or other carcinomas that overexpress HER2, for whom no standard therapy was available, were treated with margetuximab by intravenous infusion at doses of 0.1-6.0 mg/kg for 3 of every 4 weeks (Regimen A) or once every 3 weeks (10-18 mg/kg) (Regimen B). RESULTS: Sixty-six patients received margetuximab (34 patients for Regimen A and 32 patients for Regimen B). The MTD was not reached for either regimen. Treatment was well-tolerated, with mostly Grade 1 and 2 toxicities consisting of constitutional symptoms such as pyrexia, nausea, anemia, diarrhea, and fatigue. Among 60 response-evaluable patients, confirmed partial responses and stable disease were observed in 7 (12%) and 30 (50%) patients, respectively; 26 (70%) of these patients had received prior HER2-targeted therapy. Tumor reductions were observed in over half (18/23, 78%) of response-evaluable patients with breast cancer including durable (>30 weeks) responders. Ex vivo analyses of patient peripheral blood mononuclear cell samples confirmed the ability of margetuximab to support enhanced ADCC compared with trastuzumab. CONCLUSIONS: Margetuximab was well-tolerated and has promising single-agent activity. Further development efforts of margetuximab as single agent and in combination with other therapeutic agents are ongoing. TRIAL REGISTRATION ID: NCT01148849.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bang YJ, Giaccone G, Im SA, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol. 2017. PMID: 28119295. doi:10.1093/annonc/mdx002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。